Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;86(4):263-276.
doi: 10.1159/000529982. Epub 2023 Mar 4.

Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis

Eva Pernicová  1   2 , Petra Macounová  3 , Martin Krsek  2 , Rastislav Maďar  1   4
Affiliations
Review

Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis

Eva Pernicová et al. Eur Neurol. 2023.

Abstract

Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment with disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration of the health condition.

Summary: Vaccination is an important preventive measure against infectious diseases. In MS patients, concerns have been raised about the effectiveness of vaccines in patients on various immunomodulatory drugs and about their possible adverse effects including impairment of neurological functions. The objectives of this article were to summarize the current knowledge on immune responses to the COVID-19 vaccines and their safety in MS patients and to provide practical guidance based on the data available to date.

Key messages: Although MS is not associated with a higher risk of COVID-19, this infection can trigger relapses or pseudo-relapses. Vaccines against SARS-CoV-2 are recommended for all MS patients who are not in the active phase of the disease, despite the fact that there is still a lack of long-term reliable data on the effectiveness and safety of vaccines against COVID-19. Some DMTs can reduce vaccine humoral responses, but might still provide some protection and adequate T-cell response. To optimize the effectiveness of vaccination, the ideal timing of vaccine application and DMTs dosing regimen is crucial.

Keywords: COVID-19; Disease-modifying therapy; Multiple sclerosis; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Flowchart showing the article selection procedure.
See this image and copyright information in PMC

References

    1. Immovilli P, Morelli N, Terracciano C, Rota E, Marchesi E, Vollaro S, et al. . Multiple sclerosis treatment in the COVID-19 era: a risk-benefit approach. Neurol Int. 2022 Apr 15;14(2):368–77. 10.3390/neurolint14020030. - DOI - PMC - PubMed
    1. Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021 Nov 15;430:120034. 10.1016/j.jns.2021.120034. - DOI - PMC - PubMed
    1. Coyle PK, Gocke A, Vignos M, Newsome SD. Vaccine considerations for multiple sclerosis in the COVID-19 era. Adv Ther. 2021 Jul;38(7):3550–88. 10.1007/s12325-021-01761-3. - DOI - PMC - PubMed
    1. Witman Tsur S, Adrian Zaher E, Tsur M, Kania K, Kalinowska-Łyszczarz A. Current immunological and clinical perspective on vaccinations in multiple sclerosis patients: are they safe after all? Int J Mol Sci. 2021 Apr 8;22(8):3859. 10.3390/ijms22083859. - DOI - PMC - PubMed
    1. Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol. 2021 Jul 15;356:577599. 10.1016/j.jneuroim.2021.577599. - DOI - PMC - PubMed

MeSH terms

Substances